<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03497611</url>
  </required_header>
  <id_info>
    <org_study_id>Conduct</org_study_id>
    <nct_id>NCT03497611</nct_id>
  </id_info>
  <brief_title>Edwards SAPIEN 3 PPI Registry</brief_title>
  <acronym>Conduct</acronym>
  <official_title>Edwards SAPIEN 3 PPI Registry - A Retrospective Survey and Prospective Identification of Procedure Related Variables Associated With Permanent Pacemaker Implantation in Patients Receiving an Edwards SAPIEN 3 Valve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Pharmakologie und Präventive Medizin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut für Pharmakologie und Präventive Medizin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are patient related risk factors for PPI that can be identified and assessed in
      retrospective pooling of 1000+ TAVI patient datasets.

      Retrospective pooling of 6 datasets already available at participating centres (4 sites in
      Germany, 1 in Zwolle / The Netherlands, 1 in Linköping / Sweden).

      Additional assessment of calcifications using a CT data core lab. Statistical analysis of the
      obtained dataset with respect to the objectives of the registry.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Permanent pacemaker implantation is a widely recognized clinical event associated with TAVI
      becoming evident within a few days after the procedure.

      While a number of registries have documented the rates of PPI with different valves, much
      less evidence has been provided for 1) patient based characteristics (e.g. RBBB etc.)
      affecting the likelihood of PPI and for 2) procedural variables (e.g. implantation depth,
      valve size etc.) that should be considered to perform an as safe and minimal invasive
      procedure as possible.

      Prior research To date there are 7 published reports on pacemaker rates and predictors
      associated with the use of the Edwards SAPIEN 3 THV (see Table). These studies suggest that
      the need for pacemaker implantation in single centers ranges between 14.4 and 20.4% derived
      from patient numbers between 131 and 335. These analyses resulted in the identification of
      pre-existing conduction disturbance / aortic valve calcification as patient related and
      implantation depth /oversizing as procedure related variables associated with Edwards SAPIEN
      3 THV TAVI. Furthermore a scoring algorithm for patient related factors has been proposed
      from a dataset of 240 patients to predict the likelihood of PPI after THV .

      Limitations of prior research Current evidence though is limited by patient numbers versus
      event rates (with a max. of 62 PPI considered in any of the available datasets) resulting in
      a limited power in multivariable analyses, the single center design of these ventures, the
      lack of a consistent definition of variables potentially associated and the unexplained
      differences in the number and type of variables identified.

      Aims For this reason the investigators consider it necessary to 1) to retrospectively pool
      data from all of these 7 datasets to arrive at a more comprehensive picture of patient
      related variables (retrospective part I), to 2) assess procedural variables in a prospective
      multicenter registry (prospective part II) and 3) to potentially validate the identified
      variables in a future prospective cohort.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2018</start_date>
  <completion_date type="Anticipated">August 3, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 3, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>occurence of PPI after TAVI</measure>
    <time_frame>30 days</time_frame>
    <description>need for permanent pacemaker implantation after TAVI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Timing of PPI</measure>
    <time_frame>30 days</time_frame>
    <description>Time interval after TAVI until PPI in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indications for PPI</measure>
    <time_frame>30 days</time_frame>
    <description>possible reasons to implant a PP:
1° AV block
complete RBBB
complete LBBB
QRS duration prolonged
LVOT calcium volume below the left and right cusp
etc</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>AV Block</condition>
  <condition>Bundle-Branch Block</condition>
  <arm_group>
    <arm_group_label>Patients with aortic stenosis</arm_group_label>
    <description>Patients receiving Edwards SAPIEN 3 Transcatheter aortic valve implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transcatheter valve implantation</intervention_name>
    <description>aortic transcatheter valve implantation using Edwards SAPIEN 3 valve</description>
    <arm_group_label>Patients with aortic stenosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that already underwent transfemoral transcatheter valve implantation with the
        SAPIEN 3 valve
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients that already underwent Edwards SAPIEN 3 implantation because of aortic
             stenosis

        Exclusion Criteria:

          -  Patients with prior pacemaker or intended valve in valve implantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Geisler, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic Tübingen, Tübingen, Germany - Department of Internal Medicine III</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maren Froehlich</last_name>
    <phone>+49 441 92517813</phone>
    <email>maren.froehlich@ippmed.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Bramlage, Prof. Dr.</last_name>
    <phone>+49 3379 3147890</phone>
    <email>peter.bramlage@ippmed.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Clinic Tübingen, Department of Internal Medicine III</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tobias Geisler, Prof</last_name>
      <phone>+49 7071 2982712</phone>
      <email>tobias.geisler@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic Ulm, Department of Internal Medicine II</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jochen Wöhrle, Prof.</last_name>
      <phone>+49 731 50045047</phone>
      <email>jochen.woehrle@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herzzentrum, Universität Köln</name>
      <address>
        <city>Cologne</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tanja Rudolph, Prof.</last_name>
      <phone>+49 221 47832396</phone>
      <email>tanja.rudolph@uk-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Klinik und Poliklinik für Erwachsene mit angeborenen und erworbenen Herzfehlern</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helmut Baumgartner, Prof.</last_name>
      <phone>+49 251 8346110</phone>
      <email>helmut.baumgartner@ukmuenster.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2018</study_first_submitted>
  <study_first_submitted_qc>April 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2018</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcatheter aortic valve implantation</keyword>
  <keyword>Pacemaker</keyword>
  <keyword>Aortic valve calcification</keyword>
  <keyword>PPI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Bundle-Branch Block</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no IPD will be made available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

